Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS -0.20%70 EV-to-OCF is 59.16 as of Jul. 19, 2026, which is 103% above its 10-year median of 29.18. GuruFocus rates FRA:PHS with a GF Score™ of 70/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, PhotoCure ASA ranks worse than 89.67% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, PhotoCure ASA's Enterprise Value is €114.89 Mil.
PhotoCure ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €1.94 Mil. Therefore, PhotoCure ASA's EV-to-OCF for today is 59.16.
The historical rank and industry rank for PhotoCure ASA's EV-to-OCF or its related term are showing as below:
FRA:PHS'
s EV-to-OCF Range Over the Past 10 Years
Min: -1419.92 Med: 29.18 Max: 1310.66
Current: 57.84
During the past 13 years, the highest EV-to-OCF of PhotoCure ASA was 1310.66. The lowest was -1419.92. And the median was 29.18.
FRA:PHS's EV-to-OCF is ranked worse than 89.67% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.55
vs FRA:PHS: 57.84
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PhotoCure ASA's PE Ratio (TTM) for today is calculated as:
PhotoCure ASA's share price for today is €5.11.
PhotoCure ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.283.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PhotoCure ASA EV-to-OCF Related Terms
PhotoCure ASA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for PhotoCure ASA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's EV-to-OCF falls into.
PhotoCure ASA's current Enterprise Value is €114.89 Mil.
PhotoCure ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (FRA:PHS) has a EV-to-OCF of 59.16 as of Jul. 19, 2026. This is 103% above median its historical median of 29.18. According to the industry distribution chart, PhotoCure ASA ranks #903 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 89.7%.
Is PhotoCure ASA's EV-to-OCF too high?
PhotoCure ASA's current EV-to-OCF of 59.16 is 103% above median its 10-year median of 29.18. The Drug Manufacturers industry median EV-to-OCF is 10.55. PhotoCure ASA's value of 59.16 is 460.8% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #903 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PhotoCure ASA has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #903 out of 1007 companies for EV-to-OCF. This places PhotoCure ASA in the lower half of its industry. The industry median EV-to-OCF is 10.55. PhotoCure ASA's value of 59.16 is 460.8% above this benchmark. While the company's 10-year median is 29.18 vs. the industry median of 10.55, PhotoCure ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.55, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current EV-to-OCF of 59.16 is 460.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current EV-to-OCF is 59.16, which is 103% above median its own 10-year median of 29.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.11 — trading 18.8% below its estimated fair value. The current EV-to-OCF is 59.16, which is 103% above median its 10-year median of 29.18 and 460.8% above the Drug Manufacturers industry median of 10.55. PhotoCure ASA's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current EV-to-OCF is 59.16 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.11 is trading 18.8% below its estimated GF Value™ of €6.29.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
EV-to-OCF: 59.16 (103% above median its 10-year median of 29.18)
GF Value™: €6.29 vs. price of €5.11 (18.8% below fair value)
Industry Position: 460.8% above the Drug Manufacturers median (#903 of 1007)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
70GF Score
Get the complete analysis for FRA:PHS
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
